– Preclinical data demonstrate pharmacodynamic activity of KRIYA-586, an investigational gene therapy which encodes for an anti-IGF1R antibody –
– Kriya anticipates advancing KRIYA-586 into the clinic in 2025 to evaluate its safety and efficacy in people suffering from TED –
Sept. 12, 2024 -- Kriya Therapeutics, Inc., (Kriya), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced preclinical data from it